AstraZeneca (AZN)
Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years
9 Meters Biopharma, Inc. (NMTRQ)
Best Budget Student Laptops for Academic Success in 2025
9 Meters Biopharma, Inc. (NMTRQ)
Best Business Office Monitors for Professional Workspaces in 2025
9 Meters Biopharma, Inc. (NMTRQ)
Best Business Laptops for Professional Productivity in 2025
9 Meters Biopharma, Inc. (NMTRQ)
Best Closed Back Headphones for Audio Isolation and Quality (2025)
9 Meters Biopharma, Inc. (NMTRQ)
Under Desk Treadmills: Top Models and Buying Guide
Altimmune Inc (ALT)
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
BridgeBio Pharma (BBIO)
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
Johnson & Johnson (JNJ)
Johnson & Johnson - RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
Johnson & Johnson (JNJ)
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer